It can cost tens of millions to develop medical devices and bring them to market. It may cost $1 billion or more to develop drugs. Companies that can provide early life science companies with financial components that facilitate this process can ease the road to market. Discussions on early life science investments and banking platform approaches can be a resource for entrepreneurs in biotechnology, diagnostics and other life science companies that need to be a focus of webinars sponsored by fintech companies, which provides a webinar that provides a platform for banking services.
The conversation is scheduled on May 8 at 1 p.m. ET, including Breyer Capital’s healthcare and life sciences head Morgan Cheatham, founder and executive partner Gurdane Bhutani, MBX Capital’s founder and executive partner, and will be hosted by Mercury Healthcare and Life Sciences Ben Kromnick.
The key points of the conversation are:
- With the cuts in NIH grants, what are the opportunities for private institutions to step in?
- How to develop a strategy to evaluate angel investors, SBIR grants and strategic investors
- The trend of decreasing government investment in R&D and the rise of AI challenges and opportunities for companies – how do they manage them?
- Mercury’s role in helping companies pose financial challenges from the financial challenges required by any company’s financial workflow, enabling them to clearly understand and access the HLS financial markets through their ecosystem and expertise.
- How Mercury works with life science incubators and accelerators such as mass challenge and cancer X
To sign up for a webinar, how Fintech makes early life science companies easier to grow, fill out the following form:
Mercury is a financial technology company, not a bank. Choose banking services provided by financial groups,,,,, List. ,, and Evolution Bank and Trust, Member FDIC.
